GT Biopharma Appoints Two New Independent Directors

About this update from Gt Biopharma, Inc.

[{"type":"text","content":"BEVERLY HILLS, Calif., Jan. 19, 2021 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology platform today announced the appointment of Michael Breen and Rajesh Shrotriya MD to the Company's Board of Directors (the \"Board\"), effective immediately. \nMr. Breen and Dr. Shrotriya bring strong operational skills, deep understanding of drug development and significant leadership experience to the Board. \n\"We are pleased to welcome Michael and Rajesh to the GT Biopharma Board,\" said Anthony Cataldo, Chairman and Chief Executive Officer of GT Biopharma. \"As part of our transition to NASDAQ we have now reconstituted our board. Michael and Rajesh bring unique skills and expertise, as well as significant experience serving on boards of directors of public companies, which will complement our Board's existing capabilities. With the addition of Michael and Rajesh, we are confident our Board will be well-positioned to oversee the Company's ongoing initiatives.\"\nAbout Michael Breen\nMichael Breen is an English qualified solicitor/attorney and was formerly the Managing Director of the Sports and Entertainment Division of Bank Insinger de Beaufort N. V., which is a wealth management organization and was part of BNP Paribas Group, one of the world's largest banks. The holding company Insinger de Beaufort Holdings S.A. was listed on the Luxembourg Stock Exchange. Mr. Breen was also a director and major shareholder of an affiliate of Insinger de Beaufort Holdings S.A.\nMr. Breen is a former senior equity partner in the 400+ partner and 50+ office law firm of Clyde & Co, whose head office is based in the City of London, England.\nAbout Rajesh Shrotriya\nRajesh Shrotriya MD, served most recently (2002-2017) as Chairman of the Board and Chief Executive Officer of Spectrum Pharmaceuticals, Inc., an oncology focused NASDAQ listed company. Prior to that he was President and Operating Officer of NeoTherapeutics, Inc. In this capacity he spearheaded major changes in business strategy and made structural reorganization culminating in the formation of Spectrum Pharmaceuticals, Inc.\nPreviously, Dr. Shrotriya was Executive Vice President and Chief Scientific Officer for SuperGen, Inc. and Vice President, Medical Affair...

More updates from Gt Biopharma, Inc.